Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
| 2.97 | |
| 3.36 | |
| - | |
| 3.39 | |
| 2.9 | |
| 2.1-60 | |
| 3 115 K | |
| 0.1217 | |
| 1 049 K | |
| 0 | |
| -1.258 | |
| 97.481 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Investing.com – U.S. stocks were mixed after the close on Thursday, as gains in the Oil&Gas, Industrials and Basic Materials sectors led shares higher while losses in the Technology, Telecoms and Co...
Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Consumer Goods, Oil&Gas and Technology sectors led shares higher. At the close in NYSE, the Dow Jones Industrial A...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
